Treatment With Recombinant Human Growth Hormone During Childhood and CV Risk in Early Adulthood
Children treated with recombinant human growth hormone were found to be at increased risk for cardiovascular events during early adulthood.
Children treated with recombinant human growth hormone were found to be at increased risk for cardiovascular events during early adulthood.
Patients undergoing transcatheter pulmonary valve replacement using a Sapien valve had satisfactory short-term clinical outcomes.
In this phase 2 trial, patients with hypercholesterolemia and clinical atherosclerotic cardiovascular disease were recruited from 85 sites across 20 countries.
Low-intensity warfarin therapy was found to be as effective as standard-intensity I warfarin in lowering the risk for thromboembolism in older patients with nonvalvular atrial fibrillation.
The use of paclitaxel-coated vs uncoated endovascular devices for the treatment of peripheral artery disease was not associated with increased mortality.
A novel vs reference DAPT regimen after staged PCI was found to reduce the risk for bleeding in patients with acute coronary syndrome.
A long-term very low carbohydrate dietary intervention was associated with a reduction in the concentration of small LDL particles in patients with type 2 diabetes.
Age at diagnosis, but not duration, of hypertension was found to be associated with cognitive decline.
Individuals living with HIV, particularly those with comorbid kidney disease, were found to be at increased risk for cardiovascular disease.
A new dissociated pulmonary vein activity was detected in a patient.